论文信息 - The Missing Link in the Diagnostic Pathway of Prostate Cancer - 字舞流文

The Missing Link in the Diagnostic Pathway of Prostate Cancer

S. Høyer | L. Hegyi | A. V. Wøyen | Gergely Laczkó

[1] R. Baertsch,et al. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). , 2015 .

[2] P. Vlachostergios,et al. Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives , 2015, Front. Oncol..

[3] C. Liang,et al. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma , 2014, Molecular Cancer Research.

[4] A. Lopez‐Beltran,et al. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. , 2014, Biochimica et biophysica acta.

[5] H. Beltran,et al. The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression , 2014, Front. Oncol..

[6] W. Lowrance,et al. Castration-resistant prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[7] K. Do,et al. Treatment outcomes of small cell carcinoma of the prostate , 2007, Cancer.

[8] M. Wakefield,et al. Unusual and underappreciated: small cell carcinoma of the prostate. , 2007, Seminars in oncology.

[9] A. Shabsigh,et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. , 1999, The Journal of urology.